The earliest discovery of genetic aberrations associated with hematological malignancy was the (9;22) translocation or Philadelphia chromosome, resulting in a fusion between the genes coding for BCR and ABL1, identifying patients with chronic myelogenous leukemia (CML). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.